Clinical Trials Logo
  1. Home
  2. CIN2
  3. NCT04687267

Conservative Management of CIN2 Lesions and Biomarkers Evaluation

CIN2 Clinical Trial

Official title:
Gestione Conservativa di Lesioni CIN2 e Valutazione di Biomarcatori Indicativi di Regressione

Clinical Trial Summary

Prospective study including women aged 25-45 years, adherent to the cervical screening program of four different centers of the Veneto region, with a diagnosis of CIN2 lesion. After enrollment according to predefined criteria, and informed consent to participate, the CIN2 lesions are managed by follow-up; cases with progressive lesions will be treated immediately, cases with CIN2 persistence for more than 12 months will be treated as well. Viral, molecular and immunocytochemical biomarkers will be studied, and evaluated in relation to the clinical outcome.

Clinical Trial Description

Women aged 25-45 years, adherent to the organized population-based cervical screening program, with a histological diagnosis of CIN2 and fulfilling the inclusion criteria will be invited to participate to the study, previously providing specific information; in case of acceptance, informed consent is signed. STUDY PROTOCOL: The adherent women will attend periodical control visits: - every 6 months up to 24 months, with performance of: pap test (PT) and colposcopy (with biopsy in case of visible alterations); - at 6 and 12 months control visit: a liquid-based sample of cervical cells will be collected for the biomarkers' analyses. BIOMARKERS: 1. - HPV search and partial HPV16/18 genotyping, by cobas 4800 high-risk HPV assay (Roche); PCR with MY09/MY11 consensus primers and full genotyping by restriction fragment length analysis, plus PCR with beta-globin primers (in-house); 2. - methylation analysis of the cellular genes FAM194A and hsa-mir124-2, by methylation-specific quantitative PCR test (qMSP - QIAsure methylation test, Qiagen); 3. - methylation analysis of the L1 and L2 viral genes of HPV types 16 and 18, by pyrosequencing; 4. - immunocytochemical analysis for p16INK4A/Ki67 proteins (dual stain), by p16INK4A/Ki67 immunocytochemical analysis by CINtec Plus kit (Roche). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04687267
Study type Observational
Source Istituto Oncologico Veneto IRCCS
Contact
Status Completed
Phase
Start date April 15, 2019
Completion date December 31, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT05372016 - Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Phase 3
Recruiting NCT05027776 - Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years Phase 3
Recruiting NCT06147388 - Regression of Cervical Precancerous Lesions and Associated Risk Factors
Completed NCT03676101 - Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Phase 1
Recruiting NCT04895020 - Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years Phase 3
Completed NCT04425291 - Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Phase 3
Active, not recruiting NCT01881659 - Cervical Cancer Screening With Human Papillomavirus Testing
Recruiting NCT05371353 - Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
Recruiting NCT05413798 - Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa N/A
Recruiting NCT05413811 - Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living With HIV N/A
Completed NCT03177863 - Expectancy as Alternative to Treatment for Cervical Intraepithelial Neoplasia Grade 2 Among Women 25 - 30 Years of Age N/A
Not yet recruiting NCT06210074 - Performance of Tampons as a Biospecimen Collection Tool for the Detection of Human Papillomavirus in a Colposcopy Setting N/A
Terminated NCT05584332 - A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females Phase 3
Recruiting NCT02956031 - Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women.
Recruiting NCT04422366 - Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Phase 3
Completed NCT02405533 - Phase II Evaluation of AHCC for the Eradication of HPV Infections N/A